Quoin Pharmaceuticals Ltd. Statistics
Share Statistics
Quoin Pharmaceuticals Ltd. has 5.36M shares outstanding. The number of shares has increased by 303.15% in one year.
| Shares Outstanding | 5.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 4.85% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.88M |
| Failed to Deliver (FTD) Shares | 793 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 19.17K, so 0.38% of the outstanding shares have been sold short.
| Short Interest | 19.17K |
| Short % of Shares Out | 0.38% |
| Short % of Float | 0.49% |
| Short Ratio (days to cover) | 0.2 |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is -0.51.
| PE Ratio | -0.51 |
| Forward PE | -0.51 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.78 |
| P/FCF Ratio | -0.56 |
| PEG Ratio | n/a |
Enterprise Valuation
Quoin Pharmaceuticals Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.15, with a Debt / Equity ratio of 0.
| Current Ratio | 3.15 |
| Quick Ratio | 3.15 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.53% and return on capital (ROIC) is -165.91%.
| Return on Equity (ROE) | -1.53% |
| Return on Assets (ROA) | -0.71% |
| Return on Capital (ROIC) | -165.91% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.17M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 22.38K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.69% in the last 52 weeks. The beta is 1.89, so Quoin Pharmaceuticals Ltd.'s price volatility has been higher than the market average.
| Beta | 1.89 |
| 52-Week Price Change | -84.69% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 46.64 |
| Average Volume (20 Days) | 2.98M |
Income Statement
In the last 12 months, Quoin Pharmaceuticals Ltd. had revenue of $0 and earned -$8.69M in profits. Earnings per share was $-9.64.
| Revenue | 0 |
| Gross Profit | -103.44K |
| Operating Income | -9.38M |
| Net Income | -8.69M |
| EBITDA | -9.27M |
| EBIT | - |
| Earnings Per Share (EPS) | -9.64 |
Balance Sheet
The company has $2.40M in cash and $3.52K in debt, giving a net cash position of $2.40M.
| Cash & Cash Equivalents | 2.40M |
| Total Debt | 3.52K |
| Net Cash | 2.40M |
| Retained Earnings | -46.20M |
| Total Assets | 11.39M |
| Working Capital | 7.02M |
Cash Flow
In the last 12 months, operating cash flow was -$7.86M and capital expenditures $0, giving a free cash flow of -$7.86M.
| Operating Cash Flow | -7.86M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.86M |
| FCF Per Share | -8.73 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
QNRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1460.61% |
| FCF Yield | -220.84% |
Analyst Forecast
The average price target for QNRX is $4, which is 506.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 506.1% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 18, 2023. It was a backward split with a ratio of 1:12.
| Last Split Date | Jul 18, 2023 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -8.04 |
| Piotroski F-Score | 1 |